Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on May 8, 2019. The filing addresses a change in the Company's operating and reporting segments effective for the period ending March 30, 2019, and includes recast historical financial data to ensure comparability.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references Exhibit 99.1, which contains select segment financial metrics for the three months ended April 2, 2016, through March 30, 2019, and the fiscal years ended December 31, 2016, 2017, and 2018.
The Company utilizes non-GAAP financial measures to supplement GAAP reporting, including:
- Adjusted gross profit and adjusted operating income
- Adjusted net income and adjusted diluted earnings per share
- Adjusted gross margin and adjusted operating margin
- Net sales excluding held-for-sale businesses
- Constant currency net sales growth
Material Changes Versus Prior Period
The primary material change reported is a reorganization of operating segments to reflect how management makes operating decisions and allocates resources. The changes include:
- Consumer Self-Care Americas (CSCA): Formerly Consumer Healthcare Americas; covers OTC, contract manufacturing, infant formula, and animal health in the U.S., Mexico, and Canada.
- Consumer Self-Care International (CSCI): Formerly Consumer Healthcare International; covers branded consumer self-care in Europe, the U.K., and Australia, plus liquid licensed products in the U.K.
- Prescription Pharmaceuticals (RX): Now includes the Company's U.S. prescription business and the Israeli diagnostic business, which was previously reported within the CSCI segment.
The Company states that these segment changes have no impact on the consolidated financial position, results of operations, or cash flows. Historical data has been recast to align with the new structure.
Guidance, Outlook, and Management Commentary
Management commentary focuses on the rationale for the segment changes and the utility of non-GAAP measures. The Company asserts that non-GAAP measures exclude items that obscure underlying operational trends, such as:
- Amortization expense related to acquired intangible assets
- Operating results from held-for-sale businesses
- Acquisition and integration-related charges and contingent consideration adjustments
- Restructuring charges and termination benefits
- Unusual litigation and impairment charges
- Gains or losses on divestitures
These measures are used by management for planning, forecasting, and determining compensation. The filing does not contain specific forward-looking guidance or numerical outlooks for future periods.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific recast financial metrics and segment data referenced in this filing.
- Verify the reconciliation of non-GAAP measures to GAAP measures provided in the full report to understand the magnitude of excluded items.
- Confirm the impact of the Israeli diagnostic business transfer on the Prescription Pharmaceuticals segment's historical performance.
- Consult the Annual Report on Form 10-K for the year ended December 31, 2018, and relevant Form 10-Q filings for complete financial context.